| WARF: P01018US |  |
| Use of 2Alpha-Methyl-19-Nor-20(S)-1 Alpha, 25-Dihydroxyvitamin D3 to Increase Bone Strength |
| INVENTORS | • | Hector DeLuca, Connie Smith |
The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing a new 19-nor vitamin D compound that is extremely effective in increasing bone density without affecting serum calcium levels.
OVERVIEW
Vitamin D (1,25-dihydroxyvitamin D3) is a highly potent regulator of calcium homeostasis and plays an established role in cellular differentiation. A recently discovered class of vitamin D analogs, the 19-nor-vitamin D compounds, shows a selective activity profile with high potency in inducing cellular differentiation, making these analogs potentially useful for treating a number of disorders.
THE INVENTION
UW-Madison researchers have developed a new 19-nor vitamin D compound, 2alpha-methyl-19-nor-20(S)-1alpha,25-dihydroxyvitamin D3 (2AMD). It is characterized by the presence of a methylene substituent at C-2 and an unnatural configuration of the methyl group at C-20. 2AMD shows activity similar to that of 1,25-dihydroxyvitamin D3 in stimulating intestinal calcium transport, but is 100 times more potent in stimulating calcium mobilization of bone. This results in a novel therapeutic agent for treating diseases where bone formation is desired, particularly osteoporosis. 2AMD increases both breaking and crushing strength of bones, suggesting its use in conjunction with bone replacement surgeries, such as hip and knee replacements. This compound also exhibits high cell differentiation activity, making it potentially useful as an anti-cancer agent and in the treatment of some skin diseases.
APPLICATIONS
- Preferred therapeutic agent for treating osteoporosis, osteomalacia and renal osteodystrophy
- May also be useful for improving bone fracture healing and bone grafts
- Potential anti-cancer agent, especially against leukemia and colon, breast and prostate cancers
- May be useful for treating skin diseases, such as psoriasis, as well as skin conditions such as wrinkles, slack skin, dry skin and insufficient sebum secretion
- Potential for treating immune disorders in humans, including multiple sclerosis, lupis, diabetes mellitus, host-versus-graft reaction and organ transplant rejection
- Prospective treatment for inflammatory diseases such as rheumatoid arthritis, asthma and inflammatory bowel diseases
- May be used to treat other disorders, including acne, alopecia and hypertension
KEY BENEFITS
- Extremely effective in increasing bone density without affecting serum calcium levels
- Useful in increasing both percent ash and total ash of the femur
- Successful in increasing bone breaking strength of the femur and vertebral body
- Compound may be administered transdermally, orally or parenterally.
ADDITIONAL INFORMATION
For More Information About the Inventors
Intellectual Property Status
Tech Fields
Pharmaceuticals & Vitamin D - Musculoskeletal
Pharmaceuticals & Vitamin D - Vitamin D
CONTACT INFORMATION
For current licensing status, please contact our team at
licensing@warf.org
or phone 608.262.4924. (Clicking this link will open a contact form in a popup window. If you have problems viewing the form, try disabling your popup blocker software.)
WARF: A Leader in Technology Transfer Since 1925
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
Since its founding as the patenting and licensing arm of the University of Wisconsin-Madison, WARF has been working with business and industry to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.
The University of Wisconsin and WARF -
A Single Location to Accelerate Translational Development of New Drugs
The UW-Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities in the country, UW-Madison offers state-of-the-art facilities unmatched by most public universities.
These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW-Madison with a complete translational research facility; and soon, the Wisconsin Institutes for Discovery, made up of innovative private and public interdisciplinary biomedical research institutes. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.
